Imunon, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations
Imunon, Inc. (IMNN) reported Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations of 10.14 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations · last filed 2026-03-31
- Imunon, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, expirations for the quarter ending 2025-12-31 was 0.00 shares.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, expirations for the quarter ending 2023-12-31 was 0.00 shares.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, expirations for the quarter ending 2023-09-30 was 0.00 shares.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, expirations for the quarter ending 2023-06-30 was 4.40K shares.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, expirations for fiscal 2025 was 10.14K shares, a 2560.63% increase from fiscal 2024.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, expirations for fiscal 2024 was 381.00 shares, a 95.50% decline from fiscal 2023.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, expirations for fiscal 2023 was 8.46K shares, a 16.31% increase from fiscal 2022.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, non-option equity instruments, expirations for fiscal 2022 was 7.27K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 10.14K shares 10-K · filed 2026-03-31 | |||
| 2025-09-30 | 10.14K shares 10-Q · filed 2025-11-13 | ||||
| 2024-12-31 | 381.00 shares 10-K · filed 2026-03-31 | 5.00K shares 10-K · filed 2025-02-27 | |||
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 0.00 shares derived: sum of 2 quarters · filed 2025-02-27 | 4.40K shares derived: sum of 3 quarters · filed 2025-02-27 | 8.46K shares 10-K · filed 2025-02-27 | |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | 4.40K shares derived: sum of 2 quarters · filed 2023-11-14 | 8.46K shares 10-Q · filed 2023-11-14 | ||
| 2023-06-30 | 4.40K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 8.46K shares 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | 4.06K shares 10-Q · filed 2023-05-11 | ||||
| 2022-12-31 | 7.27K shares 10-K · filed 2024-03-28 | ||||
| 2019-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-19 | 0.00 shares derived: sum of 2 quarters · filed 2021-03-19 | 1.17M shares 10-K · filed 2021-03-19 | ||
| 2019-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | 1.17M shares 10-Q · filed 2019-11-14 | |||
| 2019-06-30 | 1.17M shares 10-Q · filed 2019-08-14 | ||||
| 2018-12-31 | 13.93K shares 10-K · filed 2020-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |